Description: Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXA™, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain.
Home Page: www.scilexholding.com
SCLX Technical Analysis
960 San Antonio Road
Palo Alto,
CA
94303
United States
Phone:
650-516-4310
Officers
| Name | Title |
|---|---|
| Mr. Jaisim Shah | Pres, CEO & Director |
| Mr. Suresh K. Khemani | Sr. VP & Chief Commercial Officer |
| Dr. Dmitri V. Lissin M.D. | Sr. VP & Chief Medical Officer |
| Dr. Henry H. Ji Ph.D. | Exec. Chairman |
| Ms. Elizabeth Adkins Czerepak M.B.A. | Exec. VP, CFO, Chief Bus. Officer & Sec. |
| Dr. Suketu D. Desai Ph.D. | Chief Technical Officer & Sr. VP |
| Mr. Steven F. Lincoln J.D. | Gen. Counsel & Chief Compliance Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 14.1851 |
| IPO Date: | 2021-03-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 85 |